205 related articles for article (PubMed ID: 27009140)
21. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer.
Harano K; Lei X; Gonzalez-Angulo AM; Murthy RK; Valero V; Mittendorf EA; Ueno NT; Hortobagyi GN; Chavez-MacGregor M
Breast Cancer Res Treat; 2016 Sep; 159(2):367-74. PubMed ID: 27522517
[TBL] [Abstract][Full Text] [Related]
23. Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis.
Stewart P; Blanchette P; Shah PS; Ye XY; Boldt RG; Fernandes R; Vandenberg T; Raphael J
Breast; 2020 Dec; 54():203-210. PubMed ID: 33130486
[TBL] [Abstract][Full Text] [Related]
24. POU4F1 confers trastuzumab resistance in HER2-positive breast cancer through regulating ERK1/2 signaling pathway.
Wu D; Jia HY; Wei N; Li SJ
Biochem Biophys Res Commun; 2020 Dec; 533(3):533-539. PubMed ID: 32988584
[TBL] [Abstract][Full Text] [Related]
25. Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006-2014).
Daniels B; Kiely BE; Houssami N; Lord SJ; Dobbins T; Lu CY; Ward RL; Pearson SA
Br J Cancer; 2018 Feb; 118(3):441-447. PubMed ID: 29136405
[TBL] [Abstract][Full Text] [Related]
26. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
[TBL] [Abstract][Full Text] [Related]
27. The interaction between carcinoembryonic antigen-related cell adhesion molecule 6 and human epidermal growth factor receptor 2 is associated with therapeutic efficacy of trastuzumab in breast cancer.
Iwabuchi E; Miki Y; Kanai A; Miyashita M; Kijima G; Hirakawa H; Suzuki T; Ishida T; Sasano H
J Pathol; 2018 Nov; 246(3):379-389. PubMed ID: 30058236
[TBL] [Abstract][Full Text] [Related]
28. Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.
Lambertini M; Ferreira AR; Poggio F; Puglisi F; Bernardo A; Montemurro F; Poletto E; Pozzi E; Rossi V; Risi E; Lai A; Zanardi E; Sini V; Ziliani S; Minuti G; Mura S; Grasso D; Fontana A; Del Mastro L
Oncologist; 2015 Aug; 20(8):880-9. PubMed ID: 26099741
[TBL] [Abstract][Full Text] [Related]
29. Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
Li C; Wang B; Chen SC; Wada R; Lu D; Wang X; Polhamus D; French J; Vadhavkar S; Strasak A; Smitt M; Joshi A; Samant M; Quartino A; Jin J; Girish S
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1079-1090. PubMed ID: 29022084
[TBL] [Abstract][Full Text] [Related]
30. Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer.
Yang HY; Ma D; Liu YR; Hu X; Zhang J; Wang ZH; Di GH; Hu XC; Shao ZM
Sci Rep; 2017 Apr; 7(1):1134. PubMed ID: 28442763
[TBL] [Abstract][Full Text] [Related]
31. Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016).
Daniels B; Kiely BE; Lord SJ; Houssami N; Lu CY; Ward RL; Pearson SA
Breast Cancer Res Treat; 2018 Aug; 171(1):151-159. PubMed ID: 29736743
[TBL] [Abstract][Full Text] [Related]
32. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
Farhat F; Kattan JG; Ghosn M
Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
[TBL] [Abstract][Full Text] [Related]
33. Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.
Strasser-Weippl K; Horick N; Smith IE; O'Shaughnessy J; Ejlertsen B; Boyle F; Buzdar AU; Fumoleau P; Gradishar W; Martin M; Moy B; Piccart-Gebhart M; Pritchard KI; Lindquist D; Rappold E; Finkelstein DM; Goss PE
Eur J Cancer; 2016 Mar; 56():85-92. PubMed ID: 26829011
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
Kiess AP; McArthur HL; Mahoney K; Patil S; Morris PG; Ho A; Hudis CA; McCormick B
Cancer; 2012 Apr; 118(8):1982-8. PubMed ID: 21887681
[TBL] [Abstract][Full Text] [Related]
35. Deciphering trastuzumab resistance in residual tumor according to HER2 status after neoadjuvant trastuzumab containing regimen in HER2 positive breast cancer patients might help to choose further adjuvant anti-HER2 treatment.
Abduyev Z; Altundag K
J BUON; 2019; 24(5):2208. PubMed ID: 31786900
[No Abstract] [Full Text] [Related]
36. [Real-life study of 7-year survival in patients treated with trastuzumab for HER2+ early breast cancer].
Saghatchian M; Curtit E; Coeffic D; Flinois A; Levy C
Bull Cancer; 2020; 107(7-8):745-755. PubMed ID: 32532419
[TBL] [Abstract][Full Text] [Related]
37. Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials.
Gyawali B; Niraula S
Cancer Treat Rev; 2017 Nov; 60():18-23. PubMed ID: 28863313
[TBL] [Abstract][Full Text] [Related]
38. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
[TBL] [Abstract][Full Text] [Related]
39. HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis.
Xu QQ; Pan B; Wang CJ; Zhou YD; Mao F; Lin Y; Guan JH; Shen SJ; Zhang XH; Xu YL; Zhong Y; Wang XJ; Zhang YN; Sun Q
Oncotarget; 2016 Sep; 7(39):63571-63582. PubMed ID: 27566580
[TBL] [Abstract][Full Text] [Related]
40. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
